Compare TECH & RVTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | RVTY |
|---|---|---|
| Founded | 1976 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.7B |
| IPO Year | 1995 | 1994 |
| Metric | TECH | RVTY |
|---|---|---|
| Price | $51.74 | $98.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 16 |
| Target Price | $71.82 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 2.8M | 1.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.62% | 0.34% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.81 | 0.36 |
| Revenue | $1,219,635,000.00 | ★ $3,311,822,000.00 |
| Revenue This Year | $2.49 | $6.37 |
| Revenue Next Year | $6.40 | $5.10 |
| P/E Ratio | ★ $65.60 | $284.43 |
| Revenue Growth | ★ 5.23 | N/A |
| 52 Week Low | $43.20 | $81.22 |
| 52 Week High | $72.16 | $118.30 |
| Indicator | TECH | RVTY |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 51.58 |
| Support Level | $49.98 | $94.04 |
| Resistance Level | $57.86 | $102.68 |
| Average True Range (ATR) | 1.88 | 3.34 |
| MACD | 0.81 | 0.03 |
| Stochastic Oscillator | 84.03 | 40.54 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.